UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials

Clinical infectious diseases, 2020-09, Vol.71 (6), p.1379-1389

2020

Volltextzugriff (PDF)

Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection

The New England journal of medicine, 2022-05, Vol.386 (19), p.1793-1803

2022

Volltextzugriff (PDF)

Weight Change Following Antiretroviral Therapy Switch in People With Viral Suppression: Pooled Data from Randomized Clinical Trials

Clinical infectious diseases, 2021-10, Vol.73 (8), p.1440-1451

2021

Volltextzugriff (PDF)

HIV pre-exposure prophylaxis (PrEP): a review of current knowledge of oral systemic HIV PrEP in humans

Infection, 2016-04, Vol.44 (2), p.151-158

2016

Volltextzugriff (PDF)

Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trials

AIDS (London), 2019-07, Vol.33 (9), p.1455-1465

2019

Volltextzugriff (PDF)

HIV pre-exposure prophylaxis (PrEP): a review of current knowledge of oral systemic HIV PrEP in humans

Infection, 2016-04, Vol.44 (2), p.151-158

2016

Volltextzugriff (PDF)

Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial

The lancet HIV, 2018-07, Vol.5 (7), p.e357-e365

2018

Volltextzugriff (PDF)

Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial

The lancet HIV, 2019-06, Vol.6 (6), p.e364-e372

2019

Volltextzugriff (PDF)

Gesundheitsvorsorge bei HIV-Infizierten

MMW Fortschritte der Medizin, 2017-06, Vol.159 (Suppl 2), p.14-23

Stellbrink, Hans-Jürgen

2017

Volltextzugriff (PDF)

Short-Term Neuropsychiatric Tolerability of Bictegravir Combined with Emtricitabine/Tenofovir Alafenamide in Clinical Practice

Antiviral therapy, 2020-01, Vol.25 (2), p.83-90

2020

Volltextzugriff (PDF)

German-Austrian guidelines on anal dysplasia and anal cancer in HIV-positive individuals: prevention, diagnosis, and treatment

Journal der Deutschen Dermatologischen Gesellschaft, 2015-12, Vol.13 (12), p.1302-1319

2015

Volltextzugriff (PDF)

Morbidity in older HIV-infected patients: impact of long-term antiretroviral use

AIDS reviews, 2014-04, Vol.16 (2), p.75

2014

Volltextzugriff (PDF)

Physical and mental health in HIV-infected patients with virological success and long-term exposure to antiretroviral therapy

AIDS care, 2021-04, Vol.33 (4), p.453-461

2021

Volltextzugriff (PDF)

Cabotegravir: its potential for antiretroviral therapy and preexposure prophylaxis

Current opinion in HIV & AIDS, 2018-07, Vol.13 (4), p.334-340

2018

Volltextzugriff (PDF)

Effectiveness, safety, and patient-reported outcomes of emtricitabine/tenofovir alafenamide-based regimens for the treatment of HIV-1 infection: Final 24-month results from the prospective German TAFNES cohort study

HIV medicine, 2024-10

2024

Volltextzugriff (PDF)

Bictegravir/emtricitabine/tenofovir alafenamide as initial treatment for HIV-1: five-year follow-up from two randomized trials

EClinicalMedicine, 2023-05, Vol.59, p.101991-101991, Article 101991

2023

Volltextzugriff (PDF)

Long-term effects on subclinical cardiovascular disease of switching from boosted protease inhibitors to dolutegravir

Journal of antimicrobial chemotherapy, 2023-09, Vol.78 (9), p.2361-2365

2023

Volltextzugriff (PDF)

Randomized study evaluating the efficacy and safety of switching from an an abacavir/lamivudine-based regimen to an elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide single-tablet regimen

AIDS (London), 2019-08, Vol.33 (10), p.1583-1593

2019

Volltextzugriff (PDF)

Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials

The Lancet (British edition), 2019-01, Vol.393 (10167), p.143-155

2019

Volltextzugriff (PDF)

Inversed Ratio of CD39/CD73 Expression on γδ T Cells in HIV Versus Healthy Controls Correlates With Immune Activation and Disease Progression

Frontiers in immunology, 2022-04, Vol.13, p.867167-867167

2022

Volltextzugriff (PDF)

Sofosbuvir plus velpatasvir for 8 weeks in patients with acute hepatitis C: The HepNet acute HCV-V study

JHEP reports, 2023-03, Vol.5 (3), p.100650, Article 100650

2023

Volltextzugriff (PDF)

1 – 25 von 139

Suche als RSS-Feed

Aktive Filter

ThemaMale

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(120)
Mit Volltextzugriff
(124)

Publikationsform

Sprache

Englisch
(122)
Deutsch
(15)
Russisch
(2)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials

Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection

Weight Change Following Antiretroviral Therapy Switch in People With Viral Suppression: Pooled Data from Randomized Clinical Trials

HIV pre-exposure prophylaxis (PrEP): a review of current knowledge of oral systemic HIV PrEP in humans

Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trials

HIV pre-exposure prophylaxis (PrEP): a review of current knowledge of oral systemic HIV PrEP in humans

Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial

Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial

Gesundheitsvorsorge bei HIV-Infizierten

Short-Term Neuropsychiatric Tolerability of Bictegravir Combined with Emtricitabine/Tenofovir Alafenamide in Clinical Practice

Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label phase 3 FLAIR study

Incidence of Hypertension and Blood Pressure Changes in Persons With Human Immunodeficiency Virus at High Risk for Cardiovascular Disease Switching From Boosted Protease Inhibitors to Dolutegravir: A Post-hoc Analysis of the 96-week Randomised NEAT-022 Trial

German-Austrian guidelines on anal dysplasia and anal cancer in HIV-positive individuals: prevention, diagnosis, and treatment

Morbidity in older HIV-infected patients: impact of long-term antiretroviral use

Physical and mental health in HIV-infected patients with virological success and long-term exposure to antiretroviral therapy

Cabotegravir: its potential for antiretroviral therapy and preexposure prophylaxis

Effectiveness, safety, and patient-reported outcomes of emtricitabine/tenofovir alafenamide-based regimens for the treatment of HIV-1 infection: Final 24-month results from the prospective German TAFNES cohort study

Bictegravir/emtricitabine/tenofovir alafenamide as initial treatment for HIV-1: five-year follow-up from two randomized trials

Long-term effects on subclinical cardiovascular disease of switching from boosted protease inhibitors to dolutegravir

Randomized study evaluating the efficacy and safety of switching from an an abacavir/lamivudine-based regimen to an elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide single-tablet regimen

Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials

Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials

Inversed Ratio of CD39/CD73 Expression on γδ T Cells in HIV Versus Healthy Controls Correlates With Immune Activation and Disease Progression

Switching from efavirenz, emtricitabine, and tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study

Sofosbuvir plus velpatasvir for 8 weeks in patients with acute hepatitis C: The HepNet acute HCV-V study

Aktive Filter

Suchergebnisse filtern